HC Wainwright Issues Pessimistic Estimate for DRTS Earnings

Key Points

• HC Wainwright trimmed its Q1 2026 EPS estimate for Alpha Tau Medical (DRTS) to ($0.13) from ($0.12), now forecasting ($0.13) each quarter and a FY2026 EPS of ($0.53), while maintaining a Buy rating and a $12 price target.
• Alpha Tau reported ($0.14) EPS for the latest quarter, missing consensus by $0.01; the street consensus for the current full year is ($0.45), the average analyst rating is Hold with a $8.67 target, and the stock trades around $7.04 with a ~$597M market cap.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) - Investment analysts at HC Wainwright cut their Q1 2026 EPS estimates for shares of Alpha Tau Medical in a research report issued on Tuesday, March 10th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.13) per share for the quarter, down from their prior estimate of ($0.12). HC Wainwright currently has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Alpha Tau Medical's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Alpha Tau Medical's Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.53) EPS.

A number of other analysts have also recently issued reports on the company. Zacks Research raised Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 17th. Piper Sandler reaffirmed a "neutral" rating and set a $5.00 target price on shares of Alpha Tau Medical in a report on Wednesday, March 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a research report on Wednesday, January 21st. Finally, Citigroup increased their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $8.67.

Alpha Tau Medical Price Performance

Alpha Tau Medical stock opened at $7.04 on Thursday. The firm has a market capitalization of $597.13 million, a P/E ratio of -13.28 and a beta of 1.02. Alpha Tau Medical has a one year low of $2.30 and a one year high of $8.60. The business has a fifty day moving average price of $7.01 and a 200-day moving average price of $5.11.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings data on Wednesday, March 11th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01).

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors and hedge funds have recently made changes to their positions in DRTS. Millennium Management LLC grew its position in Alpha Tau Medical by 185.7% during the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company's stock worth $534,000 after buying an additional 70,081 shares in the last quarter. Mariner LLC raised its holdings in shares of Alpha Tau Medical by 1.6% in the 4th quarter. Mariner LLC now owns 125,165 shares of the company's stock valued at $620,000 after acquiring an additional 1,915 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Alpha Tau Medical by 291.7% in the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock valued at $116,000 after acquiring an additional 17,500 shares in the last quarter. Trifecta Capital Advisors LLC bought a new stake in shares of Alpha Tau Medical during the 4th quarter valued at about $48,000. Finally, Daytona Street Capital LLC bought a new stake in shares of Alpha Tau Medical during the 4th quarter valued at about $749,000. Hedge funds and other institutional investors own 2.65% of the company's stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.